1. What is the HOMA-IR Index?

The HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) index is a method used to quantify insulin resistance and beta-cell function. It provides an estimate of insulin resistance from fasting blood glucose and insulin levels.

2. How Does the Calculator Work?

The calculator uses the HOMA-IR equation:

Where:

• Fasting Insulin — Measured in μU/L (microinternational units per liter)
• Fasting Glucose — Measured in mmol/L (millimoles per liter)
• 22.5 — Normalization constant

Interpretation: Values below 2.5 are generally considered normal, while higher values indicate increasing levels of insulin resistance.

3. Importance of HOMA-IR Calculation

Details: HOMA-IR is a valuable tool for assessing insulin resistance, which is associated with metabolic syndrome, type 2 diabetes, cardiovascular disease, and other metabolic disorders.

4. Using the Calculator

Tips: Enter fasting insulin in μU/L and fasting glucose in mmol/L. Both values must be greater than zero for accurate calculation.

5. Frequently Asked Questions (FAQ)

Q1: What is considered a normal HOMA-IR value?
A: Typically, values below 2.5 are considered normal. Values between 2.5-5.0 indicate mild insulin resistance, while values above 5.0 suggest significant insulin resistance.

Q2: When should I get my insulin and glucose levels tested?
A: Testing should be done after an overnight fast (8-12 hours) for accurate results. Avoid food, beverages (except water), and strenuous exercise before testing.

Q3: Are there limitations to the HOMA-IR calculation?
A: While useful for population studies and clinical screening, HOMA-IR may not be as accurate as more complex tests like hyperinsulinemic-euglycemic clamp for individual diagnosis.

Q4: Can medications affect HOMA-IR results?
A: Yes, medications that affect insulin sensitivity or glucose metabolism (such as metformin, insulin, or corticosteroids) can influence HOMA-IR values.

Q5: How often should HOMA-IR be monitored?
A: Frequency depends on individual risk factors and clinical context. Typically, it may be monitored every 6-12 months in individuals with insulin resistance or metabolic disorders.